New oral drug targets DNA repair in Hard-to-Treat cancers

NCT ID NCT06606990

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing an experimental oral drug called pidnarulex in 40 people with advanced solid tumors that have spread and stopped responding to standard treatments. The drug works by blocking an enzyme that cancer cells need to divide and repair their DNA. The study aims to find the best dose, check safety, and see how the drug affects tumors and DNA repair markers in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pidnarulex (CX-5461), an oral drug that blocks an enzyme involved in cell division and DNA repair
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early phase 1 trial with only 40 participants, so the drug may not prove effective or safe enough to move forward. Side effects are unknown at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT SOLID NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Cancer Institute Developmental Therapeutics Clinic

    RECRUITING

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.